Biosyent Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.74
- Today's High:
- $5.74
- Open Price:
- $5.74
- 52W Low:
- $4.6132
- 52W High:
- $6.2854
- Prev. Close:
- $5.74
- Volume:
- 0
Company Statistics
- Market Cap.:
- $67.09 million
- Book Value:
- 2.758
- Revenue TTM:
- $27.93 million
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $22.86 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- 11.24%
- Return on Equity TTM:
- 16.82%
Company Profile
Biosyent Inc. had its IPO on under the ticker symbol BIOYF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Biosyent Inc. has a staff strength of 0 employees.
Stock update
Shares of Biosyent Inc. opened at $5.74 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.74 - $5.74, and closed at $5.74.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Biosyent Inc. have increased by +0.53%.
Biosyent Inc.'s Key Ratios
Biosyent Inc. has a market cap of $67.09 million, indicating a price to book ratio of 2.5633 and a price to sales ratio of 2.2727.
In the last 12-months Biosyent Inc.’s revenue was $27.93 million with a gross profit of $22.86 million and an EBITDA of $7.26 million. The EBITDA ratio measures Biosyent Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Biosyent Inc.’s operating margin was 0% while its return on assets stood at 11.24% with a return of equity of 16.82%.
In Q1, Biosyent Inc.’s quarterly earnings growth was a negative -34.3% while revenue growth was a positive 3.4%.
Biosyent Inc.’s PE and PEG Ratio
- Forward PE
- 13.1926
- Trailing PE
- 18.5
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.3 per share while it has a forward price to earnings multiple of 13.1926 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biosyent Inc.’s profitability.
Biosyent Inc. stock is trading at a EV to sales ratio of 1.6432 and a EV to EBITDA ratio of 5.1632. Its price to sales ratio in the trailing 12-months stood at 2.2727.
Biosyent Inc. stock pays annual dividends of $0 per share, indicating a yield of 2.18% and a payout ratio of 23.13%.
Balance sheet and cash flow metrics
- Total Assets
- $38.75 million
- Total Liabilities
- $3.95 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $96021
- Dividend Payout Ratio
- 23.13%
Biosyent Inc. ended 2024 with $38.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $38.75 million while shareholder equity stood at $33.42 million.
Biosyent Inc. ended 2024 with $0 in deferred long-term liabilities, $3.95 million in other current liabilities, 5329817.00 in common stock, $26.22 million in retained earnings and $0 in goodwill. Its cash balance stood at $6.42 million and cash and short-term investments were $26.25 million. The company’s total short-term debt was $176,169 while long-term debt stood at $0.
Biosyent Inc.’s total current assets stands at $35.59 million while long-term investments were $0 and short-term investments were $19.83 million. Its net receivables were $4.22 million compared to accounts payable of $3.57 million and inventory worth $4.71 million.
In 2024, Biosyent Inc.'s operating cash flow was $0 while its capital expenditure stood at $96021.
Comparatively, Biosyent Inc. paid $0.23 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.74
- 52-Week High
- $6.2854
- 52-Week Low
- $4.6132
- Analyst Target Price
- $
Biosyent Inc. stock is currently trading at $5.74 per share. It touched a 52-week high of $6.2854 and a 52-week low of $6.2854. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $5.61 and 200-day moving average was $5.56 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4077.1% of the company’s stock are held by insiders while 131.2% are held by institutions.
Frequently Asked Questions About Biosyent Inc.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency, as well as Feramax Pd Maintenance 45, a chewable, orange-flavored iron supplement. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.